Literature DB >> 27328428

Comorbid anxiety-like behavior and locus coeruleus impairment in diabetic peripheral neuropathy: A comparative study with the chronic constriction injury model.

Cristina Alba-Delgado1, Alberto Cebada-Aleu2, Juan Antonio Mico3, Esther Berrocoso4.   

Abstract

Anxiety frequently appears in patients with diabetic neuropathic pain, a highly prevalent clinical condition. However, the neurobiological mechanisms of this comorbidity are poorly known. Anxiogenic phenotype has been associated with alterations of the noradrenergic locus coeruleus (LC) after peripheral nerve entrapment. We have examined the sensorial (pain) and affective (anxiety) behaviors, and the LC activity in streptozotocin (STZ)-induced diabetic rats. A comparative study with the chronic constriction injury (CCI) model of sciatic nerve was also carried out. Diabetic nociceptive hypersensitivity was observed to appear gradually, reaching their maximum at fourth week. In contrast, CCI displayed a sharp decrease in their sensorial threshold at seventh day. In both models, anxiety-like phenotype was evident after four weeks but not earlier, coincident with the LC alterations. Indeed, STZ animals showed reduced LC firing activity, tyrosine hydroxylase, pCREB and noradrenaline transporter levels, contrary to observed in CCI animals. However, in both models, enhanced LC alpha2-adrenoceptor sensitivity was presented at this time point. This study demonstrated that diabetes induced anxiety-like behavior comorbid with LC impairment at long-term. However, the nociceptive sensitivity time-course, as well as the LC functions, showed distinct features compared to the CCI model, indicating that specific neuroplastic mechanisms are at play in every model.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety-like behavior; Chronic constriction injury; Locus coeruleus; Neuropathic pain; Noradrenaline; Streptozotocin-induced diabetes

Mesh:

Substances:

Year:  2016        PMID: 27328428     DOI: 10.1016/j.pnpbp.2016.06.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain.

Authors:  Hiroyasu Murasawa; Hiroyuki Kobayashi; Kensuke Saeki; Yutaka Kitano
Journal:  Psychopharmacology (Berl)       Date:  2019-09-12       Impact factor: 4.530

2.  Opioid Activity in the Locus Coeruleus Is Modulated by Chronic Neuropathic Pain.

Authors:  Meritxell Llorca-Torralba; Fuencisla Pilar-Cuéllar; Lidia Bravo; Cristina Bruzos-Cidon; María Torrecilla; Juan A Mico; Luisa Ugedo; Emilio Garro-Martínez; Esther Berrocoso
Journal:  Mol Neurobiol       Date:  2018-10-03       Impact factor: 5.590

3.  Sulforaphane Inhibited the Nociceptive Responses, Anxiety- and Depressive-Like Behaviors Associated With Neuropathic Pain and Improved the Anti-allodynic Effects of Morphine in Mice.

Authors:  Pablo Ferreira-Chamorro; Alejandro Redondo; Gabriela Riego; Sergi Leánez; Olga Pol
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

4.  Protective Effect of Sphaerococcus coronopifolius Crude Extract in Combination with Bacillus Calmette-Guerin on Ligature-Induced Depression in Female Wistar Rats.

Authors:  Fahima Fellah; Rédha Djenidi; Imen Chebout
Journal:  Psychiatry Investig       Date:  2020-02-06       Impact factor: 2.505

Review 5.  The link between chronic pain and Alzheimer's disease.

Authors:  Song Cao; Daniel W Fisher; Tain Yu; Hongxin Dong
Journal:  J Neuroinflammation       Date:  2019-11-06       Impact factor: 8.322

6.  Altered expression of vesicular glutamate transporter-2 and cleaved caspase-3 in the locus coeruleus of nerve-injured rats.

Authors:  Lidia Bravo; Patricia Mariscal; Meritxell Llorca-Torralba; Jose María López-Cepero; Juan Nacher; Esther Berrocoso
Journal:  Front Mol Neurosci       Date:  2022-07-27       Impact factor: 6.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.